Santiago-Walker et al. evaluated anti-PD-L1 therapy outcomes in advanced BC patients with and without FGFR alternations, and the results revealed that the median overall survival in FGFR-altered patients was lower than that in FGFR-wildtype patients [61]. The gene discussed is CD274; the disease is breast cancer.